Inhibikase Therapeutics Inc（IKT）股票分析

AI 分析 of Inhibikase Therapeutics Inc (IKT)

持有

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.

估值指标

Inhibikase Therapeutics Inc（IKT）当前预期市盈率为 0.00，5 年平均预期市盈率为 -2.42。

预期市盈率

高估

5 年均值 P/E

-2.42

当前P/E

0.00

高估

-0.53

低估

-4.32

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

严重高估

5 年均值 P/S

150.84

当前P/S

826.05

高估

463.07

低估

-161.39

Alphio AI 对 IKT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%IKT

$2.41

情景价格

基

基准

基准 · 50%IKT

$2.22

情景价格

悲

悲观

悲观 · 25%IKT

$2.07

情景价格

持有 IKT 的大户

B

Blackstone Alternative Investment Advisors LLC

+ 持有IKT

-0.88%

3个月收益率

S

Soleus Capital Management, L.P.

+ 持有IKT

-7.34%

3个月收益率

A

ADAR1 Capital Management, LLC

+ 持有IKT

-14.25%

3个月收益率

IKT 常见问题 —— 由 Alphio AI 解答

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.